151 related articles for article (PubMed ID: 18755648)
1. [Targeting TNF receptors in cancer therapy: toward a new role for LIGHT and HVEM].
Pasero C; Olive D
Bull Cancer; 2008; 95(7):691-700. PubMed ID: 18755648
[TBL] [Abstract][Full Text] [Related]
2. A role for HVEM, but not lymphotoxin-beta receptor, in LIGHT-induced tumor cell death and chemokine production.
Pasero C; Barbarat B; Just-Landi S; Bernard A; Aurran-Schleinitz T; Rey J; Eldering E; Truneh A; Costello RT; Olive D
Eur J Immunol; 2009 Sep; 39(9):2502-14. PubMed ID: 19701890
[TBL] [Abstract][Full Text] [Related]
3. Targeting death receptors in bladder, prostate and renal cancer.
O'Kane HF; Watson CJ; Johnston SR; Petak I; Watson RW; Williamson KE
J Urol; 2006 Feb; 175(2):432-8. PubMed ID: 16406966
[TBL] [Abstract][Full Text] [Related]
4. A coreceptor interaction between the CD28 and TNF receptor family members B and T lymphocyte attenuator and herpesvirus entry mediator.
Gonzalez LC; Loyet KM; Calemine-Fenaux J; Chauhan V; Wranik B; Ouyang W; Eaton DL
Proc Natl Acad Sci U S A; 2005 Jan; 102(4):1116-21. PubMed ID: 15647361
[TBL] [Abstract][Full Text] [Related]
5. Role of cell death ligand and receptor system on regulation of follicular atresia in pig ovaries.
Manabe N; Matsuda-Minehata F; Goto Y; Maeda A; Cheng Y; Nakagawa S; Inoue N; Wongpanit K; Jin H; Gonda H; Li J
Reprod Domest Anim; 2008 Jul; 43 Suppl 2():268-72. PubMed ID: 18638134
[TBL] [Abstract][Full Text] [Related]
6. Herpesvirus entry mediator (HVEM) attenuates signals mediated by the lymphotoxin β receptor (LTβR) in human cells stimulated by the shared ligand LIGHT.
Bechill J; Muller WJ
Mol Immunol; 2014 Nov; 62(1):96-103. PubMed ID: 24980868
[TBL] [Abstract][Full Text] [Related]
7. [Cell death signalling: recent advances and therapeutic application].
Ségal-Bendirdjian E; Dudognon C; Mathieu J; Hillion J; Besançon F
Bull Cancer; 2005 Jan; 92(1):23-35. PubMed ID: 15689323
[TBL] [Abstract][Full Text] [Related]
8. Differential cellular expression of LIGHT and its receptors in early gestation human placentas.
Gill RM; Coleman NM; Hunt JS
J Reprod Immunol; 2007 Jun; 74(1-2):1-6. PubMed ID: 17010447
[TBL] [Abstract][Full Text] [Related]
9. The HVEM network: new directions in targeting novel costimulatory/co-inhibitory molecules for cancer therapy.
Pasero C; Speiser DE; Derré L; Olive D
Curr Opin Pharmacol; 2012 Aug; 12(4):478-85. PubMed ID: 22445654
[TBL] [Abstract][Full Text] [Related]
10. TNF family members and malaria: old observations, new insights and future directions.
Randall LM; Engwerda CR
Exp Parasitol; 2010 Nov; 126(3):326-31. PubMed ID: 20433831
[TBL] [Abstract][Full Text] [Related]
11. The TRAIL apoptotic pathway in cancer onset, progression and therapy.
Johnstone RW; Frew AJ; Smyth MJ
Nat Rev Cancer; 2008 Oct; 8(10):782-98. PubMed ID: 18813321
[TBL] [Abstract][Full Text] [Related]
12. Signaling through death receptors in cancer therapy.
Fulda S; Debatin KM
Curr Opin Pharmacol; 2004 Aug; 4(4):327-32. PubMed ID: 15251124
[TBL] [Abstract][Full Text] [Related]
13. The promise of cancer therapeutics targeting the TNF-related apoptosis-inducing ligand and TRAIL receptor pathway.
Wang S
Oncogene; 2008 Oct; 27(48):6207-15. PubMed ID: 18931688
[TBL] [Abstract][Full Text] [Related]
14. Creation of a LIGHT mutant with the capacity to evade the decoy receptor for cancer therapy.
Morishige T; Yoshioka Y; Inakura H; Tanabe A; Yao X; Tsunoda S; Tsutsumi Y; Mukai Y; Okada N; Nakagawa S
Biomaterials; 2010 Apr; 31(12):3357-63. PubMed ID: 20117833
[TBL] [Abstract][Full Text] [Related]
15. Exploring death receptor pathways as selective targets in cancer therapy.
Russo M; Mupo A; Spagnuolo C; Russo GL
Biochem Pharmacol; 2010 Sep; 80(5):674-82. PubMed ID: 20302848
[TBL] [Abstract][Full Text] [Related]
16. BTLA and HVEM cross talk regulates inhibition and costimulation.
Gavrieli M; Sedy J; Nelson CA; Murphy KM
Adv Immunol; 2006; 92():157-85. PubMed ID: 17145304
[TBL] [Abstract][Full Text] [Related]
17. Renewed interest in cancer immunotherapy with the tumor necrosis factor superfamily molecules.
Tamada K; Chen L
Cancer Immunol Immunother; 2006 Apr; 55(4):355-62. PubMed ID: 16187084
[TBL] [Abstract][Full Text] [Related]
18. Baicalein overcomes tumor necrosis factor-related apoptosis-inducing ligand resistance via two different cell-specific pathways in cancer cells but not in normal cells.
Taniguchi H; Yoshida T; Horinaka M; Yasuda T; Goda AE; Konishi M; Wakada M; Kataoka K; Yoshikawa T; Sakai T
Cancer Res; 2008 Nov; 68(21):8918-27. PubMed ID: 18974136
[TBL] [Abstract][Full Text] [Related]
19. Directing cancer cells to self-destruct with pro-apoptotic receptor agonists.
Ashkenazi A
Nat Rev Drug Discov; 2008 Dec; 7(12):1001-12. PubMed ID: 18989337
[TBL] [Abstract][Full Text] [Related]
20. HVEM/LIGHT/BTLA/CD160 cosignaling pathways as targets for immune regulation.
del Rio ML; Lucas CL; Buhler L; Rayat G; Rodriguez-Barbosa JI
J Leukoc Biol; 2010 Feb; 87(2):223-35. PubMed ID: 20007250
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
